The Evaluation of Surrogate Endpoints

1. Introduction
Geert Molenberghs, Marc Buyse, Tomasz Burzykowski

2. Setting the Scene
Geert Molenberghs, Marc Buyse, Tomasz Burzykowski

3. Regulatory Aspects in Using Surrogate Markers in Clinical Trials
Aloka Chakravarty

4. Notation and Motivating Studies
Geert Molenberghs, Marc Buyse, Tomasz Burzykowski

5. The History of Surrogate Endpoint Validation
Geert Molenberghs, Marc Buyse, Tomasz Burzykowski

6. Validation Using Single-trial Data: Mixed Binary and Continuous Outcomes
Helena Geys

7. A Meta-analytic Validation Framework for Continuous Outcomes
Geert Molenberghs, Marc Buyse, Tomasz Burzykowski

8. The Choice of Units
José Cortiñas Abrahantes, Tomasz Burzykowski, Geert Molenberghs

9. Extensions of the Meta-analytic Approach to Surrogate Endpoints
Mitch Gail

10. Meta-analytic Validation with Binary Outcomes
Didier Renard, Helena Geys

11. Validation in the Case of Two Failure-time Endpoints
Tomasz Burzykowski, José Cortiñas Abrahantes

12. An Ordinal Surrogate for a Survival True Endpoint
Tomasz Burzykowski

13. A Combination of Longitudinal and Survival Endpoints
Didier Renard

14. Repeated Measures and Surrogate Endpoint Validation
Ariel Alonso Abad, Helena Geys, Tony Vangeneugden

15. Bayesian Evaluation of Surrogate Endpoints
Ziv Shkedy, Franz Torres Barbosa

16. Surrogate Marker Validation in Mental Health
Tony Vangeneugden, Ariel Alonso Abad, Helena Geys, Annouschka Laenen

17. The Evaluation of Surrogate Endpoints in Practice: Experience in HIV
Michael D. Hughes

18. An Alternative Measure for Meta-analytic Surrogate Endpoint Validation
Tomasz Burzykowski, Marc Buyse

19. Discussion: Surrogate Endpoint Definition and Evaluation
Ross L. Prentice

20. The Promise and Peril of Surrogate Endpoints in Cancer Research
Arthur Schatzkin, Mitch Gail, Laurence Freedman

DRM-restrictions

Printing: not available
Clipboard copying: not available

Nyckelord: MATHEMATICS / Probability & Statistics / General MAT029000